The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1 Safety, Tolerability, PK & PD Study of AD-214 Administered to Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04415671
Recruitment Status : Completed
First Posted : June 4, 2020
Last Update Posted : May 6, 2022
Sponsor:
Information provided by (Responsible Party):
AdAlta Limited

Brief Summary:
This is a first in human (FIH), multi-center, dose escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of AD-214 when administered to healthy volunteers (HVs). The study in HVs will be a randomized, double blind, and placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) (Part B) study.

Condition or disease Intervention/treatment Phase
Interstitial Lung Disease Biological: AD-214 Other: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: SAD Part A in HVs- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) MAD Part B in HVs- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1, Dose-escalating Study of the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of AD-214 When Administered Intravenously to Healthy Volunteers
Actual Study Start Date : June 19, 2020
Actual Primary Completion Date : October 21, 2021
Actual Study Completion Date : February 8, 2022

Arm Intervention/treatment
Experimental: Part A- AD-214 SAD in Healthy Volunteers Biological: AD-214
AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.

Placebo Comparator: Part A-Placebo SAD in Healthy Volunteers Other: Placebo
Placebo

Experimental: Part B-AD-214 MAD in Healthy Volunteers Biological: AD-214
AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.

Placebo Comparator: Part B-Placebo MAD in Healthy Volunteers Other: Placebo
Placebo




Primary Outcome Measures :
  1. Safety and Tolerability as assessed by the number of abnormal laboratory values and/or adverse events that are related to treatment [ Time Frame: SAD Part A- 28 days. MAD Part B - 57 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Must provide signed informed consent prior to study entry and agree to adhere to all study protocol requirements.
  2. Maximum weight of 100 kg at the time of consent and body mass index (BMI) >18 and < 30 kg/m2 (inclusive)
  3. Must agree to abstain from alcohol intake from 48 hours before first study drug administration through to final study visit
  4. Must agree to abstain from smoking from 48 hours before first study drug administration through to final study visit
  5. Must have a negative urine drug screen and cotinine test, and alcohol breath test at Screening and on Day -1 (admission).
  6. Must agree to use highly effective, double barrier contraception (both male and female partners) at least 30 days prior to dosing on day 1, during the study AND for 90 days following completion of dosing
  7. Male participants must refrain from sperm donation from start of study and for 90 days after last dose of AD-214
  8. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1.
  9. Participants must be in good general health, with no significant medical history, and no clinically significant abnormalities on physical examination at Screening, and/or before administration of the initial dose of study drug.
  10. Participants must have clinical laboratory values within normal range or < 1.5 x upper limit of normal (ULN) as specified by the testing laboratory at Screening.

Exclusion Criteria:

  1. Received any Investigational Medicinal Product (IMP) within 30 days (4 months if the previous drug was a new chemical entity) or 5 half-lives prior to Screening
  2. Received an investigational vaccine within 6 months, a live attenuated vaccine within 60 days or a registered vaccine within 30 days prior to the first dose of the investigational product.
  3. Received blood products within 1 month prior to Screening.
  4. Blood donation or significant blood loss (> 450 mL) within 60 days prior to the first administration of investigational product
  5. Plasma donation within 7 days prior to the first administration of investigational product.
  6. A bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with blood draws.
  7. Known history of Human Immunodeficiency Virus (HIV) or HIV antibody positive.
  8. Hepatitis B surface Antigen (HBsAg) positive or Hepatitis B Virus (HBV) polymerase chain reaction (PCR) positivity. Hepatitis C Virus (HCV) antibody positive or HCV PCR positivity.
  9. Any clinically significant abnormality at Screening determined by medical history, physical examination, blood chemistry, hematology, coagulation, urinalysis and 12-lead electrocardiogram (ECG).
  10. A history of or current clinically significant gastrointestinal, hepatic, renal, cardiovascular, respiratory (apart from ILD), endocrine, oncological, immunodeficiency, neurological, metabolic, hematological, autoimmune or social or psychiatric condition which in the investigator's opinion may interfere with the study objectives, may put the participant at risk or may make the participant unsuitable for participation in the study.
  11. Surgery within the past 3 months prior to the first study drug administration determined by the PI to be clinically relevant.
  12. History or presence of alcohol or drug abuse
  13. Females who are pregnant or lactating.
  14. Use of any prescription or over the counter medication (with the exception of paracetamol and contraceptives) within 7 days of first study drug administration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04415671


Locations
Layout table for location information
Australia, New South Wales
Scientia Clinical Research Ltd
Randwick, New South Wales, Australia, 2031
Australia, South Australia
CMAX Clinical Research Pty Ltd
Adelaide, South Australia, Australia, 5000
Sponsors and Collaborators
AdAlta Limited
Layout table for additonal information
Responsible Party: AdAlta Limited
ClinicalTrials.gov Identifier: NCT04415671    
Other Study ID Numbers: ADA-AD-214-1A
First Posted: June 4, 2020    Key Record Dates
Last Update Posted: May 6, 2022
Last Verified: May 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Interstitial
Respiratory Tract Diseases